EODData

MEMBERSHIP REGISTER LOG IN

FRA, CNB0: FORTRESS BIOTECH.PRF.A 25

23 Dec 2025
LAST:

7.550

CHANGE:
 0.10		OPEN:
7.350		HIGH:
7.550		ASK:
0.000		VOLUME:
70
CHG(%):
1.31		PREV:
7.650		LOW:
7.350		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
23 Dec 257.3507.5507.3507.55070
22 Dec 257.4507.6507.4507.65070
19 Dec 257.4507.6007.4507.60070
18 Dec 257.5007.7007.5007.7000
17 Dec 257.3507.5507.3507.55070
16 Dec 257.7007.8507.6507.85070
15 Dec 256.2506.4006.2506.40070
12 Dec 256.2506.4006.2506.40070
10 Dec 256.2506.3506.2506.350366
09 Dec 256.3006.3506.3006.350366

PROFILE

Name:FORTRESS BIOTECH.PRF.A 25
About:Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Sector:Healthcare
Industry:Biotechnology
Address:1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154
Website:https://www.fortressbiotech.com
ISIN:US34960Q2084

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:7.610.8%
MA10:7.145.7%
MA20:6.4916.3%
MA50:6.0824.2%
MA100:6.4117.7%
MA200:6.2221.5%
STO9:80.00 
STO14:85.37 
RSI14:77.59 
WPR14:-14.63 
MTM14:1.65
ROC14:0.28 
ATR:0.31 
Week High:7.854.0%
Week Low:7.352.7%
Month High:7.854.0%
Month Low:5.5521.5%
Year High:9.4525.2%
Year Low:4.2677.4%
Volatility:22.15 

RECENT DIVIDENDS

Date Amount
14 Jun 2024$0.17
14 May 2024$0.17
12 Apr 2024$0.17
14 Mar 2024$0.17
14 Feb 2024$0.17
11 Jan 2024$0.17
14 Dec 2023$0.17
14 Nov 2023$0.17
12 Oct 2023$0.17
14 Sep 2023$0.17